Summit Therapeutics Inc.: stock overview

SMMTNASDAQHealthcare · Pharmaceutical Preparations

Price

$9.95

November 20, 2026Market cap $7.7B

What Ploutos Investor adds for Summit Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from FY2016
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 38% since Nov 4, 2026, when the 10-Q these figures come from was filed ($16.17 then, $9.95 on Nov 20, 2026). The figures date from before that move.10-Q

In short

It holds more cash than debt, by $630M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 20, 2026.

Its SEC filings
Market cap
$7.7B
775M shares
P/E
–
Revenue, 12 months
–
Net margin
–

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

Fiscal years in figures

SMMT's revenue, profit, cash flow and dividend with each year-end price, from FY2016 to 2022, 7 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $13.2B
$7.7B
Enterprise value 
$7.1B
P/E 
–
EV / EBIT 
–
EV / Revenue 
–
P/B 3-year median: 23.6
13.7
FCF yield 3-year median: -2.4%
–
Earnings yield 3-year median: -8.2%
–

Profitability

Net margin 
–
ROIC 
-129.5%
ROIC, 5-year average 
-107.4%
ROE 
-160.6%

Growth

Sorry, we do not have enough data

for the “Growth” group

Balance sheet

Cash 
$630M
Total debt 
$20M
Of which operating leases 
$20M
Net cash 
$630M
Net debt / EBITDA 
–
Interest cover 
–
Current ratio 
5.99

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+5.1%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Summit Therapeutics Inc.
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
775M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Summit Therapeutics's filings show?

These are Summit Therapeutics's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about SMMT

Didn't find what you were looking for?

Ask us
What is SMMT's market cap?

Summit Therapeutics Inc.'s market cap is $7.7B, at a price of $9.95 on November 20, 2026 and 775M shares.

Does SMMT pay a dividend?

No. Summit Therapeutics paid no regular dividend over the last 12 months.

Where do the figures come from?

From Summit Therapeutics Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.